Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 150

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 1
Chunk 150
---
157,868) 
     566%

Research
and Development Expenses

R&D expenses were $2,042,890 for nine months ended September 30, 2025 compared to $291,655 for nine
months ended September 30, 2024, representing an increase of $1,751,235, or 600%. The increase in research and development expenses was
primarily driven by costs incurred under a three-year service agreement associated with product development and distribution efforts
in the Southeast Asian market. The remainder of the increase relates to heightened R&D activities, specifically the procurement of
clinical trial supplies for our Parkinson’s disease program.

General
and Administrative Expenses

General
and administrative expenses were $4,057,046 for the nine months ended September 30, 2025 compared to $1,341,271 for the nine months ended
September 30, 2024, representing an increase of $2,715,775, or 202%. The increase is due to employees receiving their full salaries and
an accrual for a bonus in nine months ended September 30, 2025 compared to the prior period. In addition, there was an increase in legal
and professional fees in the current period compared to the prior period as a direct result of the Company being listed on Nasdaq.
Lastly, the increase in general and administrative expenses is attributed to an increase in insurance expenses and consulting fees. Overall,
this is a direct result of the Company expanding its operations in the current period compared to the prior period.

Interest
Income

Interest
income was $33,627 for the nine months ended September 30, 2025, compared to $138 for the nine months ended September 30, 2024. The increase
primarily reflects higher average cash balances and prevailing interest rates during 2025.

Interest
Expense

Interest
expense was $3,557 for the nine months ended September 30, 2025, compared to $217,821 for the nine months ended September 30, 2024, representing
a decrease of $214,264, or 98%. The significant decrease in the current period is due to the fact that none of these interest-bearing
obligations remained outstanding, as they were either repaid or converted in prior periods. As a result, the Company did not incur material
interest expense during the current period.

Loss
on Change in Fair Value of Derivative Liability

There
were no derivative liabilities during the nine months ended September